key: cord-0741262-qscbsoj7
authors: Muralidar, Shibi; Gopal, Gayathri; Visaga Ambi, Senthil
title: Targeting the viral‐entry facilitators of SARS‐CoV‐2 as a therapeutic strategy in COVID‐19
date: 2021-05-03
journal: J Med Virol
DOI: 10.1002/jmv.27019
sha: 7d1d119210bdc1de10b8b260e32fd31713529c7b
doc_id: 741262
cord_uid: qscbsoj7

Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) is the causative agent of coronavirus disease 2019 (COVID‐19) infection, which has emerged as a global pandemic causing serious concerns. Lack of specific and effective therapeutics for the treatment of COVID‐19 is a major concern and the development of vaccines is another important aspect in managing the infection effectively. The first step in the SARS‐CoV‐2 pathogenesis is the viral entry and it is mediated by its densely glycosylated spike protein (S‐protein). Similar to the SARS‐CoV, SARS‐CoV‐2 also engages angiotensin‐converting enzyme 2 (ACE2) as the host cell entry receptor. In addition to ACE2, several recent studies have implicated the crucial role of cell surface heparan sulfate (HS) as a necessary assisting cofactor for ACE2‐mediated SARS‐CoV‐2 entry. Furthermore, SARS‐CoV‐2 was also identified to use both endosomal cysteine proteases cathepsin B and L (CatB/L) and the transmembrane serine protease 2 (TMPRSS2) for the pivotal role of S‐protein priming mediating viral entry. As the entry of SARS‐CoV‐2 into host cells is mandatory for viral infection, it becomes an extremely attractive therapeutic intervention point. In this regard, this review will focus on the therapeutic targeting of the crucial steps of SARS‐CoV‐2 viral entry like S‐protein/ACE2 interaction and S‐protein priming by host cell proteases. In addition, this review will also give insights to the readers on several therapeutic opportunities, pharmacological targeting of the viral‐entry facilitators like S‐Protein, ACE2, cell surface HS, TMPRSS2, and CatB/L and evidence for those drugs currently ongoing clinical studies.

Human coronaviruses (HCoVs) like HcoV-OC43, HCoV-229E, HCoV-NL63, and HCoV-HKU1 are some previously identified CoVs that are known for its circulation among the population. Most of these HCoVs have only caused seasonal and mild respiratory tract infections that are commonly associated with symptoms of "common cold." Contradictive to these HCoVs, severe acute respiratory syndrome coronavirus (SARS-CoV), Middle-East respiratory coronavirus (MERS-CoV), and SARS-CoV-2, which have emerged in the global population over the past 20 years, are notably highly pathogenic and caused serious concern in the human population. Through their rigorous infections in human bronchial epithelial cells, upper respiratory tract, and pneumocytes, these three high pathogenic CoVs (SARS-CoV, MERS-CoV, and SARS-CoV-2) can lead to life-threatening lung injuries and respiratory pathologies. 8 As of date, specific and effec- 10 Several recent studies on cell surface heparan sulfate (HS) have implicated its role as a crucial viral-recruiting co-factor that promotes the ACE2-dependant viral entry of SARS-CoV-2. Furthermore, SARS-CoV-2 was also identified to use both endosomal cysteine proteases cathepsin B and L (CatB/L) and the transmembrane serine protease 2 (TMPRSS2) for the pivotal role of S-protein priming mediating viral entry. 6, [11] [12] [13] This review will focus on the therapeutic targeting of the crucial steps of SARS-CoV-2 viral entry like S-protein/ACE2 interaction and S-protein priming by host cell proteases. In addition, this review will also give insights to the readers on several therapeutic opportunities and pharmacological targeting of the viral-entry facilitators like S-Protein, ACE2, cell surface HS, TMPRSS2, and CatB/L.

Structurally, CoVs comprise the largest known RNA genome of 26-32 kilo-bases length. CoVs are enveloped, positive sensed, non-segmented, single-stranded RNA viruses, which encode for four vital structural proteins like nucleocapsid protein (N-protein), membrane protein (M-protein), an envelope protein (E-protein), and spike protein (S-protein). 14 Viral entry into the host cell is an essential factor for cross-species transmission, particularly for the β-CoVs. Recently, the release of the SARS-CoV-2 sequence has predicted the presence of a cleavage site for the cellular proteases. As hypothesized, the S-protein of SARS-CoV-2 contains a polybasic cleavage motif present at the S1/S2 cleavage site, which is absent in other variants of CoVs. This motif is responsible for the cleavage of the full-length S-protein into S1 and S2 subunits, mediated by the host proteases furin. 15 Thus, CoVs have an encoded S-protein with two subunits, namely S1-subunit (responsible for binding to host cell receptor) and S2subunit (responsible for the fusion of viral and cellular membranes). 16, 17 The receptor-binding domain (RBD) of the S1 subunit directly interacts and initiates direct-binding with the peptidase domain (PD) of the ACE2 receptor. Further, S1-subunit with RBD also stabilizes the prefusion state of S2-subunit, which contains the fusion machinery and other basic components necessary for membrane fusion. 14, [17] [18] [19] [20] The cleaved S-proteins are incorporated into the viral capsid during the assembly, enabling efficient entry into the cell. Proteolytic cleavage of the S-protein by furin or other cellular proteases, including TMPRSS2 can help to progress the infection as the cleavage provides two distinct functions for the subunits. It also plays an important role in the selection of host species and infection. Hence, the presence of a furin cleavage site confirms the transmission of the virus from the bat to humans. 15, 21 Further, it has been reported that the cleavage of spike protein at the S1/S2 site is crucial for the entry of the virus into the human lung cells. In addition, it was also found that the spike protein of SARS-CoV-2 contains the optimal cleavage site and follows a specific activity for different hosts, thus being an important virulent factor. The plentiful source of furin proteases in the respiratory tract, the S-protein may get cleaved upon exit from the epithelial cells, resulting in the efficient infection of the neighboring cells. 22 For the complete activation of S-protein, SARS-CoV-2 displays a dibasic cleavage site recognized not only by furin but also by other proteases, making them more pathogenic unlike other strains of CoVs. Further, acquisition of the furin cleavage site by SARS-CoV-2 is considered as the functional gain, which enables the transfer of virus from bats to humans and epidemic spread. As a consequence, the cleavage motif at the S1/ S2 site has gained significant interest in analyzing the structural loops and cleavage residues for treatment purposes. 15, 22, 23 Recently, Zhou et al., with the help of HeLa cells, confirmed that SARS-CoV-2 uses the same ACE2 receptor-like SARS-CoV. Furthermore, the same group also confirmed that conventional CoV entry receptors like aminopeptidase-N (APN) dipeptidyl peptidase-4 (DPP4) are not being engaged by SARS-CoV-2. Subsequent to receptor binding, CoV must gain access to the host cell cytosol for further pathogenesis. This could be attained by any of the two distinct viral-entry pathways, which include the CatL-mediatedendosomal pathway (where the S-protein activation is mediated by the pH-dependent endosomal protease CatL) and TMPRSS2-mediated pathway (where the S-protein activation is mediated by TMPRSS2 for subsequent entry via host plasma membrane). Several evidence have been reported on the roles of these protease activators, indicating that both TMPRSS2 and endosomal cysteine protease CatB/L are crucial for SARS-CoV-2 entry. 4, 11, [24] [25] [26] Even though the high expression of both TMPRSS2 and cathepsins have been confirmed in the lung tissues, 27 the commonly used cell lines for performing viral assays may exhibit varying expression levels of both TMPRSS2 and cathepsins, which can potentially result in a dramatic impact on the viral-entry mechanism of SARS-CoV-2. 28 Since animal models of SARS-CoV-2 are still under optimization, the controversy on the expression levels of TMPRSS2 and cathepsins in cell lines and their ability to accurately mimic aspects of the human infection still warrants investigation. Altogether, strategic selection of cell lines for the purpose of antiviral testing plays a crucial aspect in the excluding selection and screening of drugs, which could be efficiently tackled by SARS-CoV-2 by its redundant viral-entry pathways. 28 A detailed pictorial representation of the SARS-CoV-2 life cycle is given in CoV-2 and was found to potentially inhibit the SARS-CoV-2 replication by a factor of 1000-5000 times. 34, 35 Studies have also reported that the renin-angiotensin system (RAS) was found to be negatively regulated by ACE2, and further, angiotensin II (Ang II) receptor (AT2) and ACE reduces the sepsis/acid aspiration induced lung damage in the mouse. CoV also downregulates the resveratrol (RES; experimentally deactivated RAS), which can subsequently lead to an elevated level of ACE2. 36, 37 Administration of rhACE2 can potentially reduce the serum levels of AT2 by circumventing the contact between the substrate and the related enzyme (angiotensinconverting enzyme [ACE] ). This activity of rhACE2 could possibly preserve and prevent the pulmonary vascular integrity and acute respiratory distress syndrome (ARDS), respectively, by preventing the activation of host cell receptor ACE2. 34, 38 Several other specific neutralizing antibodies for SARS-CoV 42, [46] [47] [48] Furthermore, in recent computational modeling, it was suggested that nelfinavir can also target the S-protein, thereby inhibiting viral entry into the cell. 49 Nelfinavir is an antiretroviral protease inhibitor used in the treatment and prevention of human immunodeficiency virus (HIV) infection. Docking studies have revealed that nelfinavir is a potential multi-target agent. In silico approaches have confirmed the binding of nelfinavir to SARS-CoV-2 at Glu166 position and the interaction is stronger than the potent drugs lopinavir/ritonavir. Further to substantiate computational approaches, its antiviral activity was demonstrated in vitro by multiple research groups. 50 It was found that nelfinavir was three to five times more Inhibitors targeting SARS-CoV-2 main protease (M pro ) was recently identified using FRET-based assays and these M pro inhibitors include boceprevir, GC-376, calpain inhibitors II and XII. The significant discovery of calpain inhibitors II and XII suggest that it could be a feasible option to design and develop a dual inhibitor of SARS-CoV-2 M pro and the host calpains/cathepsins. 95 Further, the X-ray crystal structures of M pro with calpain inhibitors II and XII revealed that calpain XII bound to M pro in an unexpected binding mode with an inverted, semi-helical conformation where the P1′ pyridine ring has been placed in S1 pocket instead of the conventional P1 norvaline side chain. This complex structure of calpain II and XII divulges that the S1 pocket of M pro is capable of accommodating both hy- repurposed drugs for the potential treatment of SARS-CoV-2 infection. In addition to pro-viral factors, six drugs targeting the prostaglandin-endoperoxide synthase 2 (PTGS2) or cyclo-oxygenase2 (Cox-2) were also found to be of potential use, 98 in treating SARS-CoV-2 infection. A data-driven drug repositioning framework study recently identified a PARP-1 inhibitor CVL218 as a potential therapeutic agent for the treatment of COVID-19. 99 Another study using a network-based methodology involving the drug-target networks, HCoV-host interactions, HCoV-induced transcriptome in human cell lines, and human protein-protein interactome network revealed 16 repurposable drugs and 3 potential drug combinations targeting SARS-CoV-2 infection. 100 A study involving 332 high-confidence SARS-CoV-2 protein-human-protein interactions found 69 ligands that can interact with these interactions, of which 29 found to be FDA-approved drugs, 28 compounds in preclinical, and 12 are in clinical trials. 101 The outcome of this study revealed that many of these drugs need to be tested for COVID-19 and few of them have been tested in the following studies. 102, 103 Such computational studies represent a drug repurposing approach and further experimental studies using multidisciplinary approaches will pave way for repurposing FDA-approved drugs for targeting COVID-19. A summarized glance on the potential drug candidates and their clinical trial status on COVID-19 treatment are tabulated in Table 1 .

The COVID-19 outbreak is declared as a public health emergency Abbreviations: ACE2, angiotensin-converting enzyme 2; CatL/B, cathepsin L/B; CDE, Center for Drug Evaluation; HS, heparan sulfate; IFITM, interferon-inducible transmembrane; rhACE2, recombinant human angiotensin-converting enzyme 2; RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; TMPRSS2, transmembrane serine protease 2.

Novel Coronavirus (2019-nCoV) Situation Report-1, 21

World Health Organization. COVID-19 Weekly Epidemiological Update 22

The emergence of COVID-19 as a global pandemic: understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science (80-)

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science (80-)

ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome

Coronavirus biology and replication: implications for SARS-CoV-2

Angiotensinconverting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target

Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro

SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2

Identification of a potential peptide inhibitor of SARS-CoV-2 targeting its entry into the host cells

Furin cleavage site in the SARS-CoV-2 coronavirus glycoprotein. Virol Blog Viruses Viral Dis

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Characterization of the receptorbinding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Structural basis for the recognition of the 2019-nCoV by human ACE2

The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade

Proteolytic activation of SARS-CoV-2 spike at the S1/S2 boundary: potential role of proteases beyond furin

The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin

The sequence at spike S1/S2 site enables cleavage by furin and phospho-regulation in SARS-CoV2 but not in SARS-CoV1 or MERS-CoV

Protease inhibitors targeting coronavirus and filovirus entry

Methods and protocols

Cell entry mechanisms of SARS-CoV-2

SARS-CoV-2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells

Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19

Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV

Updated Approaches against SARS-CoV-2

A review of SARS-CoV-2 and the ongoing clinical trials

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target-a perspective

Angiotensin-converting enzyme 2 protects from severe acute lung failure

A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome

A human monoclonal antibody blocking SARS-CoV-2 infection

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

Broad-spectrum coronavirus fusion inhibitors to combat COVID-19 and other emerging coronavirus diseases

Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides

Pre-fusion structure of a human coronavirus spike protein

Drug targets for corona virus: a systematic review

Tackling SARS-CoV-2: proposed targets and repurposed drugs

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Nelfinavir is active against SARS-CoV-2 in Vero E6 cells

Nelfinavir for COVID19: summary of basic science data and initial clinical experience

The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections

Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets

Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2

The mechanistic overview of SARS-CoV-2 using angiotensinconverting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system

Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters

COVID-19: drug targets and potential treatments

Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2

Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms

ACE2: the key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: demon or angel? Viruses

SARS-CoV-2: virus dynamics and host response

Single-cell RNA expression profiling shows that ACE2, the putative receptor of Wuhan 2019-nCoV, has significant expression in the nasal, mouth, lung and colon tissues, and tends to be co-expressed with HLA-DRB1 in the four tissues

Initial step of virus entry: virion binding to cell-surface glycans

Heparan sulfate proteoglycans and viral attachment: true receptors or adaptation bias? Viruses

The sweet spot: defining virus-sialic acid interactions

Review article therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: present and future

A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2

Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China

Harnessing Fc receptor biology in the design of therapeutic antibodies

Angiotensin-converting enzyme 2

Clinical & immunological erythematosus patients characteristics in systemic lupus Maryam

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor

Sructurebased discovery of a novel angiotensin-converting enzyme 2 inhibitor

IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate coreceptor

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs

Mitoxantrone affects topoisomerase activities in human breast cancer cells

Interactions of antitumor agents ametantrone and mitoxantrone (novatrone) with double-stranded DNA

TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection

Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues

Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry

The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer

TMPRSS2: potential biomarker for COVID-19 outcomes

Targeting TMPRSS2 and cathepsin B/L together may be synergistic against SARS-CoV-2 infection

Cathepsin L-selective inhibitors: a potentially promising treatment for COVID-19 patients

Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry

TMPRSS2 and COVID-19: serendipity or opportunity for intervention?

Coronavirusesdrug discovery and therapeutic options

Targeting TMPRSS2 in SARS-CoV-2 infection

Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

A small-molecule oxocarbazate inhibitor of human cathepsin L blocks severe acute respiratory syndrome and ebola pseudotype virus infection into human embryonic kidney 293T cells

Cysteine protease inhibitors cure an experimental

Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv

GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M pro and cathepsin L. bioRxiv

Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture

Host transcriptome-guided drug repurposing for COVID-19 treatment: a meta-analysis based approach

A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

A large-scale drug repositioning survey for SARS-CoV-2 antivirals

Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol

Clinical features of 69 cases with coronavirus disease

SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention

Inhibitors of SARS-CoV-2 entry: current and future opportunities

Glycopeptide antibiotics potently inhibit cathepsin l in the late endosome/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)

Visaga Ambi S. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19

The authors express their gratitude to SASTRA-Deemed-to-be-University, Tamil Nadu, India for infrastructure and financial support.They also extend their appreciation for the contribution of Biopharmaceutical research lab members, SASTRA-Deemed-to-be-University.

The authors declare that there are no conflict of interests. Senthil Visaga Ambi https://orcid.org/0000-0003-0311-6749